BioIntercept is advancing the frontier of neuroscience by utilizing our proprietary exosome platform to target the fundamental drivers of neurodegenerative diseases. Our core mission involves engineering therapies that can effectively cross the blood-brain barrier, delivering potent regenerative and anti-inflammatory payloads directly to the central nervous system. By aiming to protect vulnerable neurons and modulate harmful neuroinflammation, we are forging new pathways for treating conditions like Alzheimer's, Parkinson's, and traumatic brain injury. This pioneering work is essential for developing a new class of therapeutics designed not only to halt disease progression but to preserve and restore critical neurological function.
Our constructs demonstrate significant improvements in:
Exosomes demonstrate VEGF modulation and endothelial stabilization in diabetic retinopathy. Topical/periocular delivery is feasible and regulatory endpoints (OCT, ERG) are well defined.
Our talented team at Biointercept Biotechnology delivers high quality services to ensure you meet your targeted results.